炎症性肠病相关药物性胰腺炎的研究进展

doi:10.3877/cma.j.issn.1674-0785.2021.03.012

炎症性肠病（IBD）是一种慢性、非特异性肠道炎症性疾病，常规治疗在使用药物快速诱导缓解后还往往需要相关药物的长期维持治疗。药物的安全性既是实现长期维持的关键，也是目前临床上终止用药的首要因素。在许多已知的IBD治疗药物的不良反应中药物性胰腺炎是一种较为严重的不良反应，常常导致停药而影响IBD患者的治疗。本文对治疗IBD的常用药物导致的药物性胰腺炎的研究进展、可能病理机制做了归纳总结，以提高临床医生的认识，加强临床监护。

关键词: 炎症性肠病, 药物性胰腺炎, 药物不良反应

Inflammatory bowel disease (IBD) is a chronic, non-specific intestinal inflammatory disease. Conventional treatment often requires long-term maintenance treatment with related drugs after rapid induction of remission. The safety of drugs is not only the key to achieving long-term maintenance, but also the primary factor for clinical drug discontinuation. Among the known adverse reactions of drugs for the treatment of inflammatory bowel disease, drug-induced pancreatitis is a serious adverse reaction, which often leads to the withdrawal of drugs and affects the treatment of patients with inflammatory bowel disease. In this paper, we summarize the research progress and possible pathological mechanism of drug-induced pancreatitis caused by commonly used drugs for the treatment of inflammatory bowel disease, in order to raise clinician's awareness of the disease and strengthen clinical monitoring.

Key words: Inflammatory bowel disease, Drug-induced pancreatitis, Adverse drug reaction

1	Pitchumoni CS, Rubin A, Das K. Pancreatitis in inflammatory bowel diseases [J]. J Clin Gastroenterol, 2010, 44(4): 246-253.
2	Tenner S. Drug induced acute pancreatitis: does it exist? [J]. World J Gastroenterol, 2014, 20(44): 16529-16534.
3	Niinomi I, Hosohata K, Oyama S, et al. Pharmacovigilance assessment of drug-induced acute pancreatitis using a spontaneous reporting database [J]. Int J Toxicol, 2019, 38(6): 487-492.
4	Badalov N, Baradarian R, Iswara K, et al. Drug-induced acute pancreatitis: an evidence-based review [J]. Clin Gastroenterol Hepatol, 2007, 5(6): 648-661, 644.
5	Simons-Linares CR, Elkhouly MA, Salazar MJ. Drug-induced acute pancreatitis in adults: an update [J]. Pancreas, 2019, 48(10): 1263-1273.
6	Sehgal P, Colombel JF, Aboubakr A, et al. Systematic review: safety of Mesalazine in ulcerative colitis [J]. Aliment Pharmacol Ther, 2018, 47(12): 1597-1609.
7	Meczker Á, Mikó A, Gede N, et al. Retrospective matched-cohort analysis of acute pancreatitis induced by 5-aminosalicylic acid-derived drugs [J]. Pancreas, 2019, 48(4): 488-495.
8	Meczker Á, Mikó A, Hegyi P. 5-ASA induces mild acute pancreatitis. Case report and review of the literature [J]. J Gastrointestin Liver Dis, 2018, 27(2): 189-194.
9	Arai Y, Arihiro S, Ide D, et al. Acute pancreatitis due to pH-dependent mesalazine that occurred in the course of ulcerative colitis [J]. Case Rep Gastroenterol, 2011, 5(3): 610-616.
10	Khanna S, Kumar A. Acute pancreatitis due to hydrocortisone in a patient with ulcerative colitis [J]. J Gastroenterol Hepatol, 2003, 18(9): 1110-1111.
11	Sadr-Azodi O, Mattsson F, Bexlius TS, et al. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: a population-based nested case-control study [J]. JAMA Intern Med, 2013, 173(6): 444-449.
12	Nango D, Nakashima H, Hirose Y, et al. Causal relationship between acute pancreatitis and methylprednisolone pulse therapy for fulminant autoimmune hepatitis: a case report and review of literature [J]. J Pharm Health Care Sci, 2018, 4: 14.
13	Yahiaoui N, Roche M, Aissaoui-Hoffmann N, et al. Intravenous methylprednisolone induced acute pancreatitis [J]. Eur J Clin Pharmacol, 2017, 73(5): 645-646.
14	Sabre A, Guthrie MM, Maleknia R. Acute necrotising pancreatitis derived from low-dose corticosteroid use: an important reminder of clinical management [J]. BMJ Case Rep, 2015, 2015: bcr2015209325.
15	Teich N, Mohl W, Bokemeyer B, et al. Azathioprine-induced acute pancreatitis in patients with inflammatory bowel diseases--a prospective study on incidence and severity [J]. J Crohns Colitis, 2016, 10(1): 61-68.
16	Wintzell V, Svanström H, Olén O, et al. Association between use of azathioprine and risk of acute pancreatitis in children with inflammatory bowel disease: a Swedish-Danish nationwide cohort study [J]. Lancet Child Adolesc Health, 2019, 3(3): 158-165.
17	Stocco G, Lanzi G, Yue F, et al. Patients' induced pluripotent stem cells to model drug induced adverse events: a role in predicting thiopurine induced pancreatitis? [J]. Curr Drug Metab, 2015, 17(1): 91-98.
18	Weersma RK, Batstra MR, Kleibeuker JH, et al. Are pancreatic autoantibodies associated with azathioprine-induced pancreatitis in Crohn's disease? [J]. JOP, 2008, 9(3): 283-289.
19	Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants [J]. Nat Genet, 2014, 46(10): 1131-1134.
20	Wilson A, Jansen LE, Rose RV, et al. HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease [J]. Aliment Pharmacol Ther, 2018, 47(5): 615-620.
21	Ledder OD, Lemberg DA, Ooi CY, et al. Are thiopurines always contraindicated after thiopurine-induced pancreatitis in inflammatory bowel disease? [J]. J Pediatr Gastroenterol Nutr, 2013, 57(5): 583-586.
22	Duan L, Ma Y, Chi J, et al. The regulatory role of immunosuppressants on immune abnormalities in acute pancreatitis [J]. Biomed Rep, 2014, 2(2): 193-198.
23	Ito T, Kimura T, Yamaguchi H, et al. Acute pancreatitis induced by cyclosporin A under stimulation of pancreas by caerulein [J]. Pancreas, 1993, 8(6): 693-699.
24	Abd-Ellah HF, Abou-Zeid NR. Role of alpha-lipoic acid in ameliorating Cyclosporine A-induced pancreatic injury in albino rats: A structural, ultrastructural, and morphometric study [J]. Ultrastruct Pathol, 2017, 41(2): 196-208.
25	Vaquero E, Molero X, Tian X, et al. Myofibroblast proliferation, fibrosis, and defective pancreatic repair induced by cyclosporin in rats [J]. Gut, 1999, 45(2): 269-277.
26	芦灵军, 李天永, 陈晓理, 等. 环孢素A对大鼠重症急性胰腺炎早期损伤和炎症反应的影响 [J]. 西部医学, 2016, 28(7): 913-916.
27	马军, 寇建涛, 张欣雪, 等. 肾移植术后重症急性胰腺炎一例 [J/OL]. 中华移植杂志(电子版), 2017, 11(4): 238-240.
28	Constantinescu AA, Abbas M, Kassem M, et al. Differential influence of tacrolimus and sirolimus on mitochondrial-dependent signaling for apoptosis in pancreatic cells [J]. Mol Cell Biochem, 2016, 418(1-2): 91-102.
29	Liu C, Dou K, Dou C, et al. Anti-inflammatory effects of tacrolimus in a rat model of acute pancreatitis [J]. Med Chem, 2010, 6(1): 37-43.
30	Werlang ME, Lewis MD, Bartel MJ. Tumor necrosis factor alpha inhibitor-induced acute pancreatitis [J]. ACG Case Rep J, 2017, 4: e103.
31	Tasci S, Senocak R, Lapsekili E, et al. The effects of a TNF-alpha inhibitor and HBO combination on the severity of pancreatitis and oxidative response in an experimental model of acute pancreatitis [J]. Bratisl Lek Listy, 2019, 120(6): 417-422.
32	Stobaugh DJ, Deepak P. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease [J]. Ann Pharmacother, 2014, 48(10): 1282-1287.
33	Lin E, Katz S. Acute pancreatitis in a patient with ulcerative colitis on Vedolizumab [J]. Inflamm Bowel Dis, 2020, 26(5): e44.
34	Picardo S, So K, Venugopal K, et al. Vedolizumab-induced acute pancreatitis: the first reported clinical case [J]. BMJ Case Rep, 2018, 2018: bcr2017222554.
35	Lopez RN, Gupta N, Lemberg DA. Vedolizumab-associated pancreatitis in paediatric ulcerative colitis: functional selectivity of the α4β7integrin and madcam-1 pathway? [J]. J Crohns Colitis, 2018, 12(4): 507-508.
36	Youssef I, Saeed N, Abdallah ME, et al. Metronidazole-induced pancreatitis: is there underrecognition? A case report and systematic review of the literature [J]. Case Rep Gastrointest Med, 2019, 2019: 4840539.
37	Tsesmeli NE, Giannoulis KE, Savopoulos CG, et al. Acute pancreatitis as a possible consequence of metronidazole during a relapse of ulcerative colitis [J]. Eur J Gastroenterol Hepatol, 2007, 19(9): 805-806.
38	Barbulescu A, Oskarsson V, Lindblad M, et al. Oral metronidazole use and risk of acute pancreatitis: a population-based case-control study [J]. Clin Epidemiol, 2018, 10: 1573-1581.
39	Sung HY, Kim JI, Lee HJ, et al. Acute pancreatitis secondary to ciprofloxacin therapy in patients with infectious colitis [J]. Gut Liver, 2014, 8(3): 265-270.
40	Marot JC, Jonckheere S, Munyentwali H, et al. Tigecycline-induced acute pancreatitis: about two cases and review of the literature [J]. Acta Clin Belg, 2012, 67(3): 229-232.

[1]	杨少鹏. 间充质干细胞来源的外泌体在炎症性肠病治疗中的作用机制及应用前景[J]. 中华细胞与干细胞杂志(电子版), 2020, 10(06): 368-372.
[2]	冯晓玲, 高鸿亮. ω-3 PUFAs对小鼠炎症性肠病调节性T细胞影响的研究[J]. 中华细胞与干细胞杂志(电子版), 2020, 10(06): 354-358.
[3]	陈文豪, 张亦超, 覃海波, 范洲, 胡航, 钱群, 江从庆, 丁召. 顺蠕动侧-侧吻合在克罗恩病结肠部分切除中的应用[J]. 中华结直肠疾病电子杂志, 2021, 10(05): 541-546.
[4]	刘欣然, 康悦, 于守江, 于永生, 刘玉伟, 王洪伟. 基于生物信息学筛选炎症相关结直肠癌基因及其特征分析[J]. 中华结直肠疾病电子杂志, 2020, 09(03): 245-253.
[5]	朱风尚, 舍玲, 丁永年, 杨长青. 警惕炎症性肠病与少见肠道疾病的鉴别诊断[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 273-276.
[6]	余佳丽, 江学良. 从炎症性肠病治疗策略转变看生物制剂应用进展[J]. 中华消化病与影像杂志(电子版), 2023, 13(03): 129-134.
[7]	廖想, 李爽, 曾瑶. 2012-2021年粪菌移植研究的趋势及热点分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(02): 93-99.
[8]	葛文松. 炎症性肠病双靶向联合治疗[J]. 中华消化病与影像杂志(电子版), 2023, 13(02): 65-67.
[9]	吕苏聪, 钟国强, 李瑾, 李明松. 炎症性肠病相关心理问题及诊治进展[J]. 中华消化病与影像杂志(电子版), 2023, 13(01): 33-38.
[10]	韦可艺, 徐昌青, 杨静. 纳米药物在炎症性肠病生物制剂靶向治疗中的应用[J]. 中华消化病与影像杂志(电子版), 2022, 12(06): 367-372.
[11]	王梦, 徐东燕, 张晓雨, 赵海剑. 伴有肛周疾病的炎症性肠病患者肛门功能及生活质量分析[J]. 中华消化病与影像杂志(电子版), 2022, 12(04): 224-227.
[12]	杨翠萍, 全旭, 孙顺昌, 张梦茵, 张金叶, 贾颖, 俞骁珺, 谢玲, 蔡波尔, 吴云林, 陈平. 上海市嘉定区炎症性肠病患者的粪便钙卫蛋白检测研究[J]. 中华消化病与影像杂志(电子版), 2021, 11(05): 193-195.
[13]	江学良. 关于制订我国炎症性肠病中西医结合质量控制标准的建议[J]. 中华消化病与影像杂志(电子版), 2020, 10(06): 241-243.
[14]	刘同亭. 加强炎症性肠病的慢病管理体系建设[J]. 中华消化病与影像杂志(电子版), 2020, 10(03): 97-100.
[15]	杨全龙, 范崇熙, 石学汇, 徐梦楠, 孙涛, 宁守斌. 炎症性肠病发病机制及与肠道菌群关系的研究进展[J]. 中华胃肠内镜电子杂志, 2022, 09(03): 148-151.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Progress in research of drug-induced pancreatitis associated with treatment of inflammatory bowel disease

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Progress in research of drug-induced pancreatitis associated with treatment of inflammatory bowel disease